缺氧诱导因子脯氨酰羟化酶抑制剂对心力衰竭患者肾功能的影响。

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure.

作者信息

Imamura Teruhiko, Ueno Yohei, Kinugawa Koichiro

机构信息

The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani Toyama, Toyama 930-0194, Japan.

出版信息

J Cardiovasc Dev Dis. 2021 Dec 17;8(12):189. doi: 10.3390/jcdd8120189.

DOI:10.3390/jcdd8120189

PMID:34940544

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8704914/

Abstract

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral agent to treat renal anemia, but its clinical implications on renal functioning in patients with heart failure remains unknown. We studied an 81-year-old man with heart failure with mildly reduced ejection fraction, chronic kidney disease, and renal anemia. The seven-month HIF-PH inhibitor daprodustat treatment improved the hemoglobin level from 7.4 g/dL to 11.8 g/dL and estimated glomerular filtration ratio from 24 mL/min/1.73 m to 35 mL/min/1.73 m without any complications, including thromboembolic events. HIF-PH inhibitor might be a promising therapeutic tool to improve renal anemia and renal function in patients with heart failure, although large-scale studies are warranted to validate our findings.

摘要

缺氧诱导因子脯氨酰羟化酶（HIF-PH）抑制剂是一种最近推出的用于治疗肾性贫血的口服药物，但其对心力衰竭患者肾功能的临床影响尚不清楚。我们研究了一名81岁男性，他患有射血分数轻度降低的心力衰竭、慢性肾脏病和肾性贫血。为期7个月的HIF-PH抑制剂达普司他治疗使血红蛋白水平从7.4 g/dL提高到11.8 g/dL，估计肾小球滤过率从24 mL/min/1.73 m²提高到35 mL/min/1.73 m²，且未出现任何并发症，包括血栓栓塞事件。HIF-PH抑制剂可能是改善心力衰竭患者肾性贫血和肾功能的一种有前景的治疗手段，不过仍需要大规模研究来验证我们的发现。